These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 3083076)
1. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. Wang WC; Ahmed N; Hanna M J Pediatr; 1986 Apr; 108(4):552-7. PubMed ID: 3083076 [TBL] [Abstract][Full Text] [Related]
2. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients. Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137 [TBL] [Abstract][Full Text] [Related]
3. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749 [TBL] [Abstract][Full Text] [Related]
4. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616 [TBL] [Abstract][Full Text] [Related]
5. Nontransferrin-bound serum iron in thalassemia and sickle cell patients. Ahmed NK; Hanna M; Wang W Int J Biochem; 1986; 18(10):953-6. PubMed ID: 3792614 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Porter JB; Walter PB; Neumayr LD; Evans P; Bansal S; Garbowski M; Weyhmiller MG; Harmatz PR; Wood JC; Miller JL; Byrnes C; Weiss G; Seifert M; Grosse R; Grabowski D; Schmidt A; Fischer R; Nielsen P; Niemeyer C; Vichinsky E Br J Haematol; 2014 Dec; 167(5):692-6. PubMed ID: 25209728 [TBL] [Abstract][Full Text] [Related]
7. High nontransferrin bound iron levels and heart disease in thalassemia major. Piga A; Longo F; Duca L; Roggero S; Vinciguerra T; Calabrese R; Hershko C; Cappellini MD Am J Hematol; 2009 Jan; 84(1):29-33. PubMed ID: 19006228 [TBL] [Abstract][Full Text] [Related]
8. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462 [TBL] [Abstract][Full Text] [Related]
9. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine. Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675 [TBL] [Abstract][Full Text] [Related]
10. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. Janka GE; Möhring P; Helmig M; Haas RJ; Betke K Eur J Pediatr; 1981 Nov; 137(3):285-90. PubMed ID: 7318841 [TBL] [Abstract][Full Text] [Related]
11. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Breuer W; Ronson A; Slotki IN; Abramov A; Hershko C; Cabantchik ZI Blood; 2000 May; 95(9):2975-82. PubMed ID: 10779448 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)]. Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638 [TBL] [Abstract][Full Text] [Related]
13. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major. Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692 [TBL] [Abstract][Full Text] [Related]
15. Progression of iron overload in sickle cell disease. Olivieri NF Semin Hematol; 2001 Jan; 38(1 Suppl 1):57-62. PubMed ID: 11206962 [TBL] [Abstract][Full Text] [Related]
16. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837 [TBL] [Abstract][Full Text] [Related]
17. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308 [TBL] [Abstract][Full Text] [Related]
18. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Hussain MA; Green N; Flynn DM; Hoffbrand AV Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469 [TBL] [Abstract][Full Text] [Related]
19. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. Srichairatanakool S; Thephinlap C; Phisalaphong C; Porter JB; Fucharoen S Med Chem; 2007 Sep; 3(5):469-74. PubMed ID: 17897073 [TBL] [Abstract][Full Text] [Related]
20. Nontransferrin-bound iron in transfused patients with sickle cell disease. Inati A; Musallam KM; Cappellini MD; Duca L; Taher AT Int J Lab Hematol; 2011 Apr; 33(2):133-7. PubMed ID: 21382180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]